On Jul. 15, 2020, Atossa Therapeutics announced successful results from in vitro testing of AT-301, Atossa’s proprietary COVID-19 nasal spray drug candidate.

The preliminary study results showed that AT-301 inhibited SARS-CoV-2 infectivity of VERO cells in a laboratory culture, which is the standard disease model used for initial screening of COVID-19 drug candidates.